The suboptimal effectiveness of available therapies for many human pathologies, strongly pushed the researchers to identify novel therapeutic approaches. In this regard, nucleic acid-based drugs (NABDs) potentially represent a novel and interesting option. NABDs, including ribozymes, DNAzymes, antisense oligonucleotides, decoy oligonucleotides, aptamers, small interfering RNAs and micro RNAs, have the capability to efficiently counteract the effects of pathogens and pathologic genes in many different experimental set-up. However, despite the potential effectiveness, NABDs use in humans is restricted to very few applications; this is mainly due to the absence of optimal release strategies. In this chapter we will illustrate the potential therapeutic value of NABDs together with the approaches followed to optimize their delivery.
Therapeutic potential and delivery strategies for nucleic acid-based drugs
GRASSI, Mario;SCAGGIANTE, BRUNA;DAPAS, BARBARA;FARRA, ROSSELLA;TONON, FEDERICA;FIORENTINO, SIMONA MARIA;ABRAMI, MICHELA;GRASSI, GABRIELE
2013-01-01
Abstract
The suboptimal effectiveness of available therapies for many human pathologies, strongly pushed the researchers to identify novel therapeutic approaches. In this regard, nucleic acid-based drugs (NABDs) potentially represent a novel and interesting option. NABDs, including ribozymes, DNAzymes, antisense oligonucleotides, decoy oligonucleotides, aptamers, small interfering RNAs and micro RNAs, have the capability to efficiently counteract the effects of pathogens and pathologic genes in many different experimental set-up. However, despite the potential effectiveness, NABDs use in humans is restricted to very few applications; this is mainly due to the absence of optimal release strategies. In this chapter we will illustrate the potential therapeutic value of NABDs together with the approaches followed to optimize their delivery.Pubblicazioni consigliate
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
